Combined, our data demonstrate that ATP13A3 silencing counters the DFMO‐induced upregulation of polyamine uptake, and enhances the efficacy of DFMO, suggesting that ATP13A3 might be a clinically relevant therapeutic target to potentiate polyamine biosynthesis inhibition approaches in neuroblastoma. The gene discussed is ATP13A3; the disease is neuroblastoma.